Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases

To evaluate tumor response, survival and adverse effects after precision radiotherapy (SBRT) in melanoma patients with ongoing PD-1 inhibitor treatment that have tumor progression.

Trial Details

NCT ID
NCT04793737
Phase
NA
Sponsor
Karolinska University Hospital
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Precision Radiation (SBRT)
Locations (sample)
  • Stockholm, Sweden|59.32938,18.06871

Key Eligibility Criteria

  • Age 18 and above
  • ECOG performance status of 0-1
  • Signed and dated written informed consent before the start of specific protocol procedures.
  • Patient has initiated PD-1 inhibitor treatment (alone or in combination with CTLA-4 inhibitor) as the first line of therapy for unresectable metast…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →